Renal Cell Carcinoma

During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated data from the CheckMate 9ER trial of patients with advanced renal cell carcinoma in the second article of a 2-part series.

Matthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma.

The panelists examine the CheckMate-67T study, which evaluated the efficacy and safety of subcutaneous versus intravenous administration of nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma.

The panelists compare the adverse event profiles of immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens, and address the economic implications of managing long-term side effects.

During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.

The primary end point of increasing progression-free survival was not met in the TiNivo-2 trial in patients with advanced metastatic renal cell carcinoma.

The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.

Medical experts specializing in clear cell renal cell carcinoma examine the concept of treatment-free survival in immunotherapy/tyrosine kinase inhibitor (IO/TKI) regimens, addressing both the advantages and potential drawbacks.

Martin H. Voss, MD, discusses the trajectory of the advanced renal cell carcinoma treatment landscape and provides clinical advice to community oncologists.

Pembrolizumab is the first agent showing overall survival benefit as adjuvant therapy in renal cell carcinoma, leading oncologists to adopt adjuvant therapy for many of their patients.

Nazli Dizman, MD, discusses the importance of the 3 main clauses of the language of respect guidelines in renal cell carcinoma.

Dr. Campbell evaluates the efficacy and safety results from the 55-month analysis of the CheckMate-9ER trial, and explores the considerations for discontinuing or continuing immunotherapy (IO) in IO/IO versus IO/TKI combination regimens.

The key opinion leaders examine the data from the KEYNOTE-426 trial, focusing on safety and efficacy outcomes along with other pertinent updates.

The FDA has granted fast track designation to ADI-270, an off-the-shelf CD70-targeted gamma delta CAR T-cell therapy, for treating metastatic or advanced clear cell renal cell carcinoma.

During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.

Combining stereotactic radiosurgery with immunotherapy significantly improves overall survival in patients with renal cell carcinoma and brain metastasis.

During a Case-Based Roundtable® event, Deepak Kilari, MD, discussed with participants how updated data on frontline regimens affects their choice of therapy for patients with metastatic clear cell renal cell carcinoma.

During a Case-Based Roundtable® event, Nizar M. Tannir, MD, discussed the importance of site of metastasis and other factors in the use of nivolumab plus ipilimumab in renal cell carcinoma in the first article of a 2-part series.

At a live virtual event, Moshe Ornstein, MD, looked at the latest data behind the 4 main combination therapies available for patients with metastatic renal cell carcinoma (RCC).

Michael Serzan, MD, discusses what a community oncologist should know about the phase 2 ARCITECT trial for patients with clear cell renal cell carcinoma.

Jaime Merchan, MD, discusses findings from an analysis presented at the 2024 ASCO Meeting.

During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed regimens for recurrent metastatic clear cell renal cell carcinoma including lenvatinib plus everolimus, belzutifan, and investigational cell therapy and bispecific agents in the second article of a 2-part series.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the takeaways from a study which examined the impact of various therapies, including combination treatments, for patients with metastatic renal cell carcinoma.

The combination therapy showed consistent benefits across various subgroups, including those with poor-risk disease and higher PD-L1 expression.

During a Case-Based Roundtable® event, Stephanie A. Berg, DO, moderated a discussion on the impact of adverse events and dosing approaches on treatment of metastatic renal cell carcinoma.